Welcome to our dedicated page for SS Innovations news (Ticker: SSII), a resource for investors and traders seeking the latest updates and insights on SS Innovations stock.
SS Innovations International Inc. (Nasdaq: SSII) is a commercial-stage surgical robotics company that develops the SSi Mantra surgical robotic system and SSi Mudra surgical instruments. Company news frequently highlights progress toward its stated goal of making robotic surgery more affordable and accessible to a larger segment of the global population.
News updates for SSII often cover developments related to the SSi Mantra platform, including new installations, clinical milestones, and telesurgery achievements. The company has reported thousands of surgical procedures performed using the SSi Mantra, including cardiac procedures and telesurgeries across categories such as pediatric, urology, gynecology, oncology, and general surgery. Announcements have also described the introduction of smaller 5-millimeter instruments designed for pediatric, cardiac, and head and neck surgery, as well as the use of the SSi Mantra Tele Surgeon Console for remote procedures.
Investors and healthcare professionals following SS Innovations can expect news on quarterly and annual financial results, including revenue from system sales, instrument sales, warranty sales, and lease income. Regulatory and clinical updates are another recurring theme, such as the completion of a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration for multiple specialty indications.
This news feed aggregates press releases, SEC-related announcements, and other public communications from SS Innovations. It provides a single location to review updates on product developments, clinical experience, regulatory milestones, and corporate events related to SSII and its surgical robotic technologies.
SS Innovations (Nasdaq: SSII) reported preliminary unaudited results for Q4 and full-year 2025 showing significant unit and revenue growth. Q4 2025 revenue is estimated at $15.0 million, up 85% from $8.1 million a year earlier, with 37 SSi Mantra installations in the quarter, up 68% year-over-year. Full-year 2025 revenue is estimated at $43.0 million, up 108% from $20.6 million in 2024, and 103 SSi Mantra installations for the year, up 119%.
The cumulative installed base reached 168 systems at year-end 2025. Management said FDA 510(k) review and EU CE marking are anticipated in the first half of 2026. Results are preliminary, unaudited and subject to final quarter-end procedures and change.
SS Innovations (Nasdaq: SSII) appointed Milan Rao as Global Chief Operating Officer and Chief Financial Officer effective January 8, 2026. The Global COO role is newly created; Mr. Rao will succeed Naveen Kumar Amar as CFO following Mr. Amar’s resignation for personal reasons and will be based in the United States during a planned transition period. Mr. Rao brings more than three decades of leadership across healthcare, technology and financial services, with prior roles at Markets and Markets, Wipro, GE Healthcare, Morgan Stanley and Citibank.
The company said Mr. Rao will support growth strategy, operational readiness and scaling of the SSi Mantra surgical robotic platform.
SS Innovations (Nasdaq: SSII) announced completion of five new 5-millimeter surgical instruments for clinical use with its SSi Mantra robotic system, targeting pediatric, cardiac, and head-and-neck procedures. The instruments are a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps.
As of Dec 31, 2025, the SSi Mantra installed base totaled 168 systems across 153 hospitals, with more than 7,800 procedures performed, including over 120 telesurgeries and more than 400 cardiac procedures. The company says the smaller instruments aim to expand robotic access for children and other patients with small anatomical structures.
SS Innovations (Nasdaq: SSII) submitted a 510(k) premarket notification to the FDA on Dec 5, 2025 for the SSi Mantra surgical robotic system covering general, urological, colorectal, gynecological and cardiac surgeries.
The company said it chose the 510(k) pathway following FDA pre-submission talks to seek faster, lower-cost review; the FDA aims for 90-day reviews but noted potential delays from the 15-day acceptance review or requests for more information. SS Innovations also expects possible EU CE marking in H1 2026.
As of Nov 30, 2025, the SSi Mantra installed base totaled 138 systems across eight countries, with 137 hospitals and over 7,300 procedures performed, including 88 telesurgeries and 390 cardiac procedures.
SS Innovations (Nasdaq: SSII) announced completion of its first telesurgery using the new SSi Mantra Tele Surgeon Console (TSC). On October 17, 2025, Dr. Sudhir Srivastava remotely performed a robotic-assisted coronary artery bypass from his residence in New Delhi on a patient about 185 miles away at Manipal Hospital in Jaipur.
The TSC is a compact, chair-based version of the SSi Mantra surgeon command center, designed for portability and smaller footprint so consoles can be placed in physician offices rather than full operating rooms. The device features lightweight glasses with magnified 3D view, magnetic sensor controls, and follows refinements made since its June 2024 showcase.
SS Innovations (Nasdaq: SSII) reported third quarter 2025 results on October 28, 2025. Q3 revenue rose 192.5% to $12.8M from $4.4M, driven by higher SSi Mantra 3 unit sales; gross profit increased 166.0% to $6.2M while gross margin narrowed to 48.1% from 52.8% a year earlier. The company reported a Q3 net loss of $3.7M (‑$0.02 per diluted share). Installations totaled 27 in Q3 (cumulative 127 across seven countries) and cumulative surgeries reached 6,057. Year-to-date revenue rose 123.0% to $28.0M. As of September 30, 2025, cash and cash equivalents were $5.7M and long-term debt was $0. Management expects to submit a 510(k) to FDA in Q4 2025 and pursue EU CE marking in H1 2026.
SS Innovations (NASDAQ: SSII) announced that its executives will participate in two investor conferences in November 2025. Dr. Sudhir Srivastava and Dr. Vishwa Srivastava will attend the UBS Global Healthcare Conference in Palm Beach Gardens on November 11, 2025 and the Stifel 2025 Healthcare Conference in New York on November 12, 2025. Management will be available for one-on-one and small group meetings on both days. A live webcast and replay of the Stifel group presentation will be accessible on the company’s investor website at https://ssinnovations.com/investor-overview/.
SS Innovations International (NASDAQ:SSII) has completed a crucial human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025. The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025, shifting from its previous De Novo pathway strategy.
The company has partnered with RQM+, a MedTech-focused CRO, for the submission process and anticipates potential FDA clearance in H1 2026. Currently, the SSi Mantra has an installed base of 125 units across 6 countries, with over 6,000 surgical procedures completed, including 60 telesurgeries and 310 cardiac procedures.
SS Innovations International (NASDAQ:SSII), a developer of surgical robotic technologies, has appointed Naveen Kumar Amar as its new Chief Financial Officer, effective September 24, 2025. Amar succeeds Dr. Vishwa Srivastava, who served as Interim CFO since July 2025 and will continue as CEO of Asia Pacific.
Amar brings over 25 years of global finance leadership experience and has been recognized as one of India's top financial executives by Forbes India, Forbes Asia, and other prestigious organizations. His expertise spans financial accounting, reporting, planning, corporate finance, and both U.S. and Indian GAAP. Prior to joining SSII, Amar provided virtual CFO services and held senior positions at SpiceXpress, Munch Ado India, and other global companies.
SS Innovations (NASDAQ: SSII) has achieved a significant milestone with the world's first pediatric pyeloplasty telesurgery using their SSi Mantra surgical robotic system. The groundbreaking procedure was performed by Dr. Chandra Mohan Vaddi, who operated remotely from Gurugram, India on a 16-month-old patient located 1,000 miles away in Hyderabad.
The company has completed over 50 telesurgeries across multiple categories including pediatric, cardiac, urology, gynecology, oncology, and general surgery, with distances reaching up to 4,000 miles. SS Innovations aims to expand its pediatric robotic surgery capabilities through the development of smaller instrumentation, furthering its mission of democratizing advanced surgical robotic care.
FAQ
What is the current stock price of SS Innovations (SSII)?
What is the market cap of SS Innovations (SSII)?
